金融界6月25日消息，上证指数低开高走，中证沪深港生物科技主题指数 (沪深港生物科技主题， 932245)报1352.64点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。当特殊情况下将对指数进行临时调整。当样本退市时，将其从指数 样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当沪股通、深 股通和港股通证券范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证沪深港生物科技主题指数十大权重分别为：恒瑞医药（12.02%）、百济神州 （10.82%）、药明康德（8.63%）、迈瑞医疗（7.04%）、信达生物（6.24%）、药明生物（4.88%）、 康方生物（3.31%）、石药集团（3.04%）、中国生物制药（2.78%）、三生制药（2.05%）。 从中证沪深港生物科技主题指数持仓的市场板块来看，香港证券交易所占比45.80%、上海证券交易所 占比33 ...

Core Viewpoint - The game rules for innovative drugs have changed by 2025, with overseas giants valuing early-stage R&D in China, prompting institutions to reassess their valuations and investment strategies [11] Group 1: Historical Context - Previously, investment institutions focused only on "quickly sellable drugs," disregarding early-stage pipelines due to high risks, with a failure rate of 90% in early projects [2] - Traditional valuation models, such as PE ratios, only considered current profits, leading to the neglect of early pipeline values in innovative drug companies [3] Group 2: Changes by 2025 - Starting in 2025, major pharmaceutical companies like Pfizer and Merck began aggressively acquiring Chinese innovative drug pipelines, especially early-stage projects, with notable transactions such as a $12.5 billion upfront payment for a PD-1/VEGF dual antibody from 3SBio, totaling $60.5 billion [4] - The technological advancements in Chinese innovative drugs have shifted from imitation to global leadership, exemplified by BeiGene's cancer drug generating $2.6 billion in annual sales in the U.S. [5] - The expiration of patents for major drugs has led to increased acquisitions from China [6] Group 3: Industry Reactions - Pharmaceutical companies are investing heavily in early-stage projects, with 35% of the 672 billion yuan spent on R&D in 2024 directed towards early-stage initiatives [7] - CRO companies are experiencing a surge in orders as pharmaceutical firms outsource early-stage research, with AI technologies reducing research timelines and increasing demand for CRO services [8] Group 4: Investment Logic Transformation - The investment logic has shifted from counting "fruits" (marketed drugs) to counting "buds" (potential future products), utilizing new algorithms like rNPV to assess pipeline success rates and future earnings [9] - The secondary market has responded positively, with the PE ratio for innovative drug stocks in Hong Kong rising from 15x to 22x [10]

Core Viewpoint - The healthcare sector is experiencing positive momentum driven by favorable policy signals and strong performance of the Hang Seng Healthcare Index and related ETFs [2][3]. Group 1: Market Performance - As of June 25, 2025, the Hang Seng Healthcare Index (HSHCI) rose by 1.37%, with notable increases in stocks such as Cloudmed (01952) up 4.52% and JD Health (06618) up 3.16% [1]. - The Hang Seng Healthcare ETF (513060) also saw a rise of 1.58%, marking its fourth consecutive increase, with a latest price of 0.58 yuan [1]. - The ETF recorded a turnover of 3.26 billion yuan, with a turnover rate of 3.98% during the trading session [1]. Group 2: Policy and Industry Insights - Recent policies from the National Medical Products Administration (NMPA) aim to streamline clinical trial approval processes, potentially reducing the time and costs associated with drug development [2]. - The China Drug Evaluation (CDE) reported a steady increase in clinical trials in oncology and autoimmune fields, indicating a growing demand for innovative drug companies and the CXO industry [2]. - The China Securities Regulatory Commission (CSRC) has introduced new listing standards for the ChiNext board, enhancing financing opportunities for unprofitable biotech companies [2]. Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF has seen a net value increase of 17.35% over the past two years, with a maximum monthly return of 28.34% since inception [3]. - The ETF's Sharpe ratio for the past year is reported at 1.66, indicating strong risk-adjusted returns [3]. - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [4]. Group 4: Valuation and Holdings - The Hang Seng Healthcare Index's latest price-to-earnings ratio (PE-TTM) stands at 27.44, which is below the historical average, suggesting a potentially undervalued market [4]. - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.34% of the index, with notable companies including Innovent Biologics (01801) and BeiGene (06160) [4].

Group 1 - The core viewpoint is that the innovative drug market is still optimistic, with ongoing revaluation of innovative drug assets and a focus on the second-generation IO and ASCO data releases, as well as the valuation reshaping of pharma companies [1][2] - The pharmaceutical index increased by 1.40% during the week of June 9-14, 2025, outperforming the CSI 300 index, which decreased by 0.25%, resulting in a relative outperformance of 1.66% [1] - The current PE (TTM) for the pharmaceutical and biological industry is 28.41 times, compared to 12.04 times for the CSI 300 index, indicating a valuation premium of 135.95% for the pharmaceutical sector, which remains at a historical low [1] Group 2 - The current innovative drug market reflects a recognition of the business model of innovative drugs, driven by leading companies like BeiGene, Innovent Biologics, and Hengrui Medicine, which are expected to turn profitable through business development or globalization in 2024 or Q1 2025 [2] - The collective rise of leading innovative drug stocks indicates a systematic revaluation of their long-term R&D investment value, with the overall valuation center of the innovative drug sector moving upward due to long-term expectations of industry upgrades [2] - The current innovative drug market is characterized by data asset pricing rather than business development pricing, where high-quality and globally leading R&D asset data will attract reasonable market valuations regardless of short-term fluctuations in business development [2]

Group 1 - The core viewpoint of the article highlights the significant performance of the CESHKB index, which has seen substantial increases over various time frames, indicating a strong market trend in the biotechnology sector in Hong Kong [1][2]. - The CESHKB index rose by 3.66% to 7559.76 points, with a trading volume of 12.113 billion [1]. - Over the past month, the CESHKB index has increased by 15.96%, by 28.51% over the last three months, and has risen 62.76% year-to-date [1]. Group 2 - The CESHKB index is compiled by China Securities Index Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1]. - The index is based on a reference date of December 12, 2014, with a base point of 2000.0 [1]. - The top ten holdings of the CESHKB index include companies such as CanSino Biologics (10.79%), Innovent Biologics (10.03%), and BeiGene (9.56%) [1]. Group 3 - The market composition of the CESHKB index is entirely based on the Hong Kong Stock Exchange [2]. - In terms of industry distribution, biopharmaceuticals account for 56.98%, pharmaceutical and biotechnology services for 24.70%, chemical drugs for 16.03%, and medical devices for 2.29% [2].

Investment Rating - The industry investment rating is maintained at "Outperform the Market" [3][82]. Core Viewpoints - The report emphasizes the significant progress of Chinese innovative drugs, highlighting their emergence as a global force in the pharmaceutical industry, supported by a solid industrial foundation, policy backing, and capital support [4][5]. - The gap between Chinese and global innovative drugs has narrowed significantly, with the time to market for first-in-class drugs reduced from over 10 years to within 1-5 years [4]. - The report indicates that Chinese companies now account for over 30% of global clinical trials, with more than 60% of popular targets being pursued by Chinese firms [35][38]. Summary by Sections Breakthrough Therapies - The development of innovative drugs in China is underpinned by a robust industrial base, supportive policies, and substantial capital investment, leading to rapid growth in the ADC market and next-generation therapies [4][12]. - Key drugs such as Keytruda and Semaglutide are projected to generate sales of $29.482 billion and $29.296 billion respectively in 2024, showcasing the potential of innovative therapies [4][12]. Achievements - Chinese innovative drugs have made significant strides, with the clinical trial participation rate increasing from 9.7% in 2016 to 28.2% in 2023 [35]. - The report notes that the number of Chinese companies involved in clinical trials for oncology drugs has risen from 15% in 2016 to 35.5% in 2023, indicating a strong focus on cancer therapies [35]. Leading Trends - The rapid growth of License Out transactions has provided substantial cash flow for innovative drug companies, facilitating their expansion into international markets [5][66]. - The report highlights that the Chinese market is still dominated by foreign patented drugs, but there is significant potential for domestic innovative drugs to capture market share, especially as many foreign drugs face expiration of patents [70][72].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 3.4% to 955.16 points, with a trading volume of 16.275 billion yuan [1] - The index has shown significant growth, increasing by 15.52% over the past month, 30.95% over the past three months, and 58.83% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (10.14%), BeiGene (9.67%), WuXi Biologics (9.53%), and others, indicating a concentration in leading firms within the innovative drug sector [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation from this market [1] - The industry composition of the index shows that drug formulations account for 42.00%, other biopharmaceuticals for 38.03%, pharmaceutical and biotechnology services for 19.53%, and vaccines for 0.44% [2] Group 3 - The index undergoes adjustments every six months, specifically on the second Friday of June and December, with weight factors adjusted accordingly [2] - In special circumstances, the index may be adjusted temporarily, such as when a sample company is delisted or undergoes mergers or acquisitions [2] - Changes in the Hong Kong Stock Connect eligibility may also lead to adjustments in the index samples [2]

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Theme Index has shown a significant increase, with a rise of 3.01% to 896.72 points on June 24, with a trading volume of 13.184 billion [1] - Over the past month, the index has increased by 7.54%, by 6.79% over the last three months, and has risen by 30.22% year-to-date [1] Index Composition - The index consists of 50 listed companies involved in medical devices, medical business and services, pharmaceuticals, and biotechnology services, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index was established on December 31, 2018, with a base point of 1000.0 [1] Top Holdings - The top ten weighted stocks in the index are: WuXi Biologics (14.49%), JD Health (10.5%), WuXi AppTec (5.95%), Alibaba Health (5.78%), Sinopharm (5.12%), Genscript Biotech (4.67%), Weigao Group (3.39%), MicroPort Scientific (2.5%), China Biologic Products (2.25%), and CanSino Biologics (2.24%) [1] Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange, with sector allocations as follows: Medical Business and Services (35.09%), Pharmaceutical and Biotechnology Services (31.59%), Medical Devices (12.87%), Chemical Drugs (12.53%), and Biological Drugs (7.91%) [2] Index Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

金融界6月24日消息，上证指数低开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1513.97点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨15.00%，近三个月上涨27.95%，年至今上 涨60.32%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。当港股通范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通生物科技主 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1]. Group 1: Fund Performance - As of June 24, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.25% and a trading volume of 2.373 billion yuan [1]. - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - The latest share count reached 1.478 billion, with a total fund size of 2.217 billion yuan as of June 23, reflecting a 273.92% increase in shares and a 486.71% increase in size since December 31, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 38.434 billion yuan, averaging 1.922 billion yuan per day [1]. - Year-to-date, the ETF has seen a total trading amount of 79.325 billion yuan over 113 trading days, averaging 0.702 billion yuan per day [1]. Group 3: Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 49.94% during the management period [1]. Group 4: Top Holdings - The ETF's top holdings include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others, with significant market values attributed to each [2].